Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. (Q37563971)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636327 AND SRC:MED&resulttype=core&format=json

3 February 2020

review article

1 reference

title

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636327 AND SRC:MED&resulttype=core&format=json

3 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636327 AND SRC:MED&resulttype=core&format=json

3 February 2020

Floriana Morgillo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636327 AND SRC:MED&resulttype=core&format=json

3 February 2020

Antonella De Luca

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636327 AND SRC:MED&resulttype=core&format=json

3 February 2020

Fortunato Ciardiello

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636327 AND SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Eric Van Cutsem

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636327 AND SRC:MED&resulttype=core&format=json

3 February 2020

Sabine Tejpar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636327 AND SRC:MED&resulttype=core&format=json

3 February 2020

language of work or name

English

0 references

publication date

28 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636327 AND SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

3 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636327 AND SRC:MED&resulttype=core&format=json

3 February 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636327 AND SRC:MED&resulttype=core&format=json

3 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636327 AND SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

519-527

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636327 AND SRC:MED&resulttype=core&format=json

EGFR antagonists in cancer treatment

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

RAS oncogenes: the first 30 years.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

K-ras is essential for the development of the mouse embryo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

K-ras is an essential gene in the mouse with partial functional overlap with N-ras

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Enzymatic coupling of cholesterol intermediates to a mating pheromone precursor and to the ras protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Hyperactive Ras in developmental disorders and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

A genetic model for colorectal tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Prevalence of ras gene mutations in human colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Poor Survival Associated with theBRAFV600E Mutation in Microsatellite-Stable Colon Cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Detection of mutated K12-ras in histologically negative lymph nodes as an indicator of poor prognosis in stage II colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Sensitive sequencing method for KRAS mutation detection by Pyrosequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Epidermal growth factor receptor: mechanisms of activation and signalling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Signal transduction and the Ets family of transcription factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Ras caught in another affair: the exchange factors for Ral.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Phospholipase C(epsilon): a novel Ras effector

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Regulation of a novel human phospholipase C, PLCepsilon, through membrane targeting by Ras

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2009.111

Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study

31 March 2020

1 reference

12 December 2020

K-ras mutations and cetuximab in colorectal cancer

1 reference

12 December 2020

Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer?

1 reference

12 December 2020

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

1 reference

12 December 2020

ras oncogenes in human cancer: a review

1 reference

12 December 2020